This inventor holds 1 USPTO granted patent. Top assignee: Leland Stanford Junior University. Active years: 2015.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2015
Title: Tatsuya Toma: Innovator in Batrachotoxin Analogues
Introduction
Tatsuya Toma is a notable inventor based in Palo Alto, CA (US). He has made significant contributions to the field of pharmacology through his innovative work on batrachotoxin analogues. His research focuses on compounds that modulate the activity of sodium channels, which are crucial for various physiological processes.
Latest Patents
Toma holds a patent for "Batrachotoxin analogues, compositions, uses, and preparation thereof." This patent includes compounds related to batrachotoxin, particularly analogs that can modulate sodium channel activity. The pharmaceutical compositions derived from his work are designed to include a pharmaceutically acceptable carrier, which may enhance transdermal permeation of the compound. These compounds are particularly useful in treating conditions that require reduced neuronal activity or muscular relaxation. They also have applications in treating ailments associated with voltage-gated sodium channel enhancement or pain.
Career Highlights
Tatsuya Toma is affiliated with Leland Stanford Junior University, where he continues to advance his research in pharmacology. His work has garnered attention for its potential therapeutic applications, particularly in the treatment of pain and related disorders.
Collaborations
Toma has collaborated with notable colleagues, including Frederic Menard and Matthew M. Logan. These collaborations have further enriched his research and contributed to the development of innovative solutions in the field.
Conclusion
Tatsuya Toma's contributions to the field of pharmacology through his work on batrachotoxin analogues highlight his role as an influential inventor. His research not only advances scientific understanding but also holds promise for developing new therapeutic treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
